JB
Highly rated in
22
conditions

Dr. James D. Battiste

Stephenson Cancer Center Brain Tumors Clinic
Oklahoma City, OK
Highly rated in
22
conditions
Specialties:Neurology
Experience:16 Years
Clinical Trials:Currently Recruiting for 7 Trials
Accepts:New PatientsMedicare
Highly rated in
22
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. James D. Battiste's experience treating your condition:
About Dr. James D. Battiste

James Battiste is a Neurologist in Oklahoma City, Oklahoma. Battiste has been practicing medicine for over 16 years and is highly rated in 22 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Awake Craniotomy. He is licensed to treat patients in Texas. Battiste is currently accepting new patients.

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 21 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. James D. Battiste it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. James D. Battiste accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health
Call to see if your plan is accepted.
Locations
800 Ne 10th St, Oklahoma City, OK 73104
Other Locations
1000 N Lincoln Blvd, Oklahoma City, OK 73104
Background & Education
Graduate Institution
University Of Texas Southwestern Medical School At Dallas, 2007
Specialties
Neurology
Licenses
Psychiatry & Neurology in TX
Hospital Affiliations
Jackson County Memorial Hospital
OU Health - University Of Oklahoma Medical Center
INTEGRIS Baptist Medical Center
Duncan Regional Hospital
Norman Regional Hospital
Oklahoma Childrens Hospital At OU Health
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Recruiting
Publish Date: December 14, 2022
Intervention Type: Biological
Study Drugs: IpilimumabNivolumab
Study Phase: Phase 2
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Enrollment Status: Recruiting
Publish Date: September 27, 2022
Intervention Type: Other, Drug
Study Drugs: VemurafenibCobimetinib
Study Phase: Phase 2
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 27, 2022
Intervention Type: Drug
Study Drugs: VismodegibGSK2256098CapivasertibAbemaciclib
Study Phase: Phase 2
Phase II Trial of Niraparib in Patients With Recurrent Glioma
Enrollment Status: Recruiting
Publish Date: July 22, 2022
Intervention Type: Drug
Study Phase: Phase 2
Feasibility Pilot Study of OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Recruiting
Publish Date: June 21, 2022
Intervention Type: Drug, Radiation
Study Drugs: OKN 007Temozolomide
Study Phase: Phase 1
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Recruiting
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drugs: AbemaciclibPaxalisibEntrectinib
Study Phase: Phase 2
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Enrollment Status: Active, not recruiting
Publish Date: December 08, 2022
Intervention Type: Radiation, Drug, Other
Study Drugs: Telaglenastat HydrochlorideTemozolomide
Study Phase: Phase 1
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Suspended
Publish Date: November 25, 2022
Intervention Type: Other, Biological, Drug, Radiation, Device
Study Drugs: IpilimumabNivolumabTemozolomide
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Active, not recruiting
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drugs: OKN-007Temozolomide (TMZ)
Study Phase: Phase 2
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active, not recruiting
Publish Date: October 12, 2022
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401INO-9012CemiplimabTemozolomide
Study Phase: Phase 1/Phase 2
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
Enrollment Status: Active, not recruiting
Publish Date: August 17, 2022
Intervention Type: Drug
Study Drug: Paxalisib (GDC-0084)
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active, not recruiting
Publish Date: July 28, 2022
Intervention Type: Other, Drug
Study Drugs: TemozolomideVeliparib
Study Phase: Phase 2/Phase 3
Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice
Enrollment Status: Active, not recruiting
Publish Date: June 30, 2022
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Enrollment Status: Active, not recruiting
Publish Date: September 28, 2021
Intervention Type: Drug
Study Drug: OKN-007
Study Phase: Phase 1
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Active, not recruiting
Publish Date: August 18, 2021
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96Bevacizumab
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: August 13, 2018
Intervention Type: Biological
Study Phase: Phase 3
An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221
Enrollment Status: Available
Publish Date: February 26, 2016
Intervention Type: Biological
View 13 Less Clinical Trials -
60 Total Publications
Polymorphous low-grade neuroepithelial tumor of the young: Rare tumor and review of the literature.
Journal: Rare tumors
Published: April 04, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
GP
Dr. Gabriel Pardo
Neurology | Ophthalmology
Highly rated in
6
conditions
Neurology
Ophthalmology

SSM Health in Oklahoma

Oklahoma Medical Research Foundation

820 Ne 15th St, 
Oklahoma City, OK 
 0.5 mi

Gabriel Pardo is a Neurologist and an Ophthalmologist in Oklahoma City, Oklahoma. Pardo has been practicing medicine for over 37 years and is highly rated in 6 conditions, according to our data. His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Optic Neuritis, and Neuromyelitis Optica. He is licensed to treat patients in Oklahoma. Pardo is currently accepting new patients.

SS
Dr. Sarah Sung
Neurology
Highly rated in
17
conditions
Neurology

OU Health

Stephenson Cancer Center Blood And Bone Marrow Cancers Clinic

800 Ne 10th St, 
Oklahoma City, OK 

Sarah Sung is a Neurologist in Oklahoma City, Oklahoma. Sung has been practicing medicine for over 12 years and is highly rated in 17 conditions, according to our data. Her top areas of expertise are Glioblastoma, Brain Tumor, Atypical Teratoid Rhabdoid Tumor (ATRT), and Neuroepithelioma. She is licensed to treat patients in Illinois. Sung is currently accepting new patients.

SZ
Dr. Salman Zubair
Neurology
Highly rated in
31
conditions
Neurology

SSM Health in Oklahoma

Northeastern Health System

800 Nw 9th St, 
Oklahoma City, OK 
 1.6 mi

Salman Zubair is a Neurologist in Oklahoma City, Oklahoma. Zubair has been practicing medicine for over 23 years and is highly rated in 31 conditions, according to our data. His top areas of expertise are Seizures, Generalized Tonic-Clonic Seizure, Memory Loss, and Migraine with Brainstem Aura. He is licensed to treat patients in Oklahoma. Zubair is currently accepting new patients.